Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas

• US 4,997,818 A
• Filed: 09/21/1989
• Issued: 03/05/1991
• Est. Priority Date: 09/21/1987
• Status: Expired due to Term

• Current Assignee: MCCAFFREY, RONALD, P., 75 EAST NEWTON STREET, BOSTON, MASSACHUSETTS 02118, SPIGELMAN, ZACHARY, 75 EAST NEWTON STREET, BOSTON, MASSACHUSETTS 02118
• Original Assignee: University Hospital Incorporated
• Inventors: Spigelman, Zachary, McCaffrey, Ronald P.
• Primary Examiner(s): Brown, Johnnie R.
• Assistant Examiner(s): Wilson, James O.
• Application Number:
  US07/099,370
• Time in Patent Office: 530 Days
• Field of Search: 514/45-51
• US Class Current: 514/45
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047

Abstract

A therapeutic method for specifically treating terminal deoxynucleotidyl transferase-positive neoplastic disease within living subjects is provided which is uniquely effective and selective. The therapeutic method comprises administering an effective concentration of a therapeutic composition to the subject, the therapeutic composition comprising a nitrogenous heterocyclic base selected from the group consisting of purines and purine derivatives and pyrimidines and pyrimidine derivatives; and a dideoxy-pentose monosaccharide moiety.

Claims

1. A therapeutic method for treating terminal deoxynucleotidyl transferase-positive leukemias and lymphomas in-situ comprising the step of:

administering a therapeutic composition to the terminal deoxynucleotidyl transferase-positive cells in-situ, said therapeutic composition comprising a nitrogeneous heterocyclic base selected from the group consisting of purines and purines derivatives, and a dideoxy-pentose monosaccharide moiety.

3. A therapeutic method as recited in claim 1 or 2 wherein said therapeutic composition further comprises a phosphoric acid moiety.

4. A therapeutic method as recited in claim 1 or 2 wherein said administration of said therapeutic composition results in an in-situ concentration of said therapeutic composition ranging from 50-150 micromoles per milliliter of fluid.

5. The therapeutic method as recited in claim 1 or 2 further comprising administering a purine deaminase inhibitor in-situ with said therapeutic composition.

2. A therapeutic method for treating terminal deoxynucleotidyl transferase-positive leukemias and lymphomas in-site comprising the step of:

administering a therapeutic composition to the terminal deoxynucleotidyl transferase-positive cells in-situ, said therapeutic composition comprising a nitrogeneous heterocyclic base selected from the group consisting of pyrimidines and pyrimidine derivatives, and a dideoxy-pentose monosaccharide moiety.